No Data
No Data
Express News | [Change Report] CANTOR FITZGERALD reports a decrease in the Shareholding of Symbio Pharmaceuticals (4582.JP) to 10.22%.
Express News | [Change Report] CANTOR FITZGERALD reports an increase in shareholding of Symbio Pharmaceuticals (4582.JP) to 11.33%.
Symbio Pharmaceuticals - The injectable drug Brincidofovir has started an international collaborative Phase Ib/II clinical trial targeting patients with malignant lymphoma in Singapore.
On the 6th, Symbio Pharmaceuticals (4582) announced the start of an international joint Phase Ib/II clinical trial in Singapore for the injectable drug Brincidofovir (IV BCV) targeted at patients with malignant lymphoma. The trial aims to evaluate the safety, tolerability, pharmacokinetics, and efficacy of IV BCV. In Phase Ib, the recommended dose will be determined, and in Phase II, the efficacy of that dose will be assessed. IV BCV has already shown effectiveness in animal studies against malignant lymphoma.
Symbio Pharmaceuticals - For the fiscal year ending December 2024, there is no significant deviation from the Financial Estimates.
On the 6th, Sinbio Pharmaceutical <4582> announced its consolidated financial results for the fiscal year ending December 2024. Revenue decreased by 56.1% year-on-year to 2.452 billion yen, with an operating loss of 3.876 billion yen (compared to the previous period's loss of 0.811 billion yen), a recurring loss of 3.689 billion yen (previously a loss of 0.736 billion yen), and a net loss attributable to shareholders of the parent company of 3.833 billion yen (previously a loss of 1.962 billion yen). Regarding the current period's business performance, currently, Treaxin (R) intravenous injection 100mg/4mL [RTD (Ready-
Nippon Steel, operating profit for the third quarter decreased by 8.5% to 566.1 billion yen.
Nippon Steel <5401> announced its third quarter results for the fiscal year ending March 2025, reporting revenue of 6 trillion 552.4 billion 98 million yen, a 1.3% decrease compared to the same period last year, and an operating profit of 566.1 billion 25 million yen, an 8.5% decrease. For the fiscal year ending March 2025, revenue is planned to be 8 trillion 600 billion yen, a 3% decrease from the previous period. Additionally, the company announced the dissolution of its mutual investment relationship with Kobe Steel <5406>, which has continued since 2002, while business collaborations will continue. A review of the relationship of group companies and policy measures is underway.
SymBio Pharmaceuticals: Summary of Financial Results for the Fiscal Year Ending 2024/12 [Japanese GAAP] (Consolidated)